↓ Skip to main content

Hereditary Tyrosinemia

Overview of attention for book
Cover of 'Hereditary Tyrosinemia'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Discovery of Hereditary Tyrosinemia in Saguenay- Lac St-Jean
  3. Altmetric Badge
    Chapter 2 Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1
  4. Altmetric Badge
    Chapter 3 Molecular Aspects of the FAH Mutations Involved in HT1 Disease
  5. Altmetric Badge
    Chapter 4 Molecular Pathogenesis of Liver Injury in Hereditary Tyrosinemia 1
  6. Altmetric Badge
    Chapter 5 Tyrosinemia and Liver Transplantation: Experience at CHU Sainte-Justine
  7. Altmetric Badge
    Chapter 6 The Liver in Tyrosinemia Type I: Clinical Management and Course in Quebec
  8. Altmetric Badge
    Chapter 7 Liver Transplantation for Hereditary Tyrosinaemia Type 1 in the United Kingdom
  9. Altmetric Badge
    Chapter 8 NTBC and Correction of Renal Dysfunction
  10. Altmetric Badge
    Chapter 9 Liver Cancer in Tyrosinemia Type 1
  11. Altmetric Badge
    Chapter 10 Neurological and Neuropsychological Problems in Tyrosinemia Type I Patients
  12. Altmetric Badge
    Chapter 11 Diagnosing Hepatorenal Tyrosinaemia in Europe: Newborn Mass Screening Versus Selective Screening
  13. Altmetric Badge
    Chapter 12 Tyrosinemia Type I in Japan: A Report of Five Cases
  14. Altmetric Badge
    Chapter 13 Newborn Screening for Hereditary Tyrosinemia Type I in Québec: Update
  15. Altmetric Badge
    Chapter 14 Hepatorenal Tyrosinemia in Mexico: A Call to Action
  16. Altmetric Badge
    Chapter 15 Hereditary Tyrosinemia Type 1 in Turkey
  17. Altmetric Badge
    Chapter 16 From Weed Killer to Wonder Drug
  18. Altmetric Badge
    Chapter 17 The Québec NTBC Study
  19. Altmetric Badge
    Chapter 18 Dietary Considerations in Tyrosinemia Type I
  20. Altmetric Badge
    Chapter 19 Remaining Challenges in the Treatment of Tyrosinemia from the Clinician’s Viewpoint
  21. Altmetric Badge
    Chapter 20 Fah Knockout Animals as Models for Therapeutic Liver Repopulation
  22. Altmetric Badge
    Chapter 21 Gene Therapy in Tyrosinemia: Potential and Pitfalls
Attention for Chapter 19: Remaining Challenges in the Treatment of Tyrosinemia from the Clinician’s Viewpoint
Altmetric Badge

Readers on

mendeley
13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Remaining Challenges in the Treatment of Tyrosinemia from the Clinician’s Viewpoint
Chapter number 19
Book title
Hereditary Tyrosinemia
Published in
Advances in experimental medicine and biology, January 2017
DOI 10.1007/978-3-319-55780-9_19
Pubmed ID
Book ISBNs
978-3-31-955779-3, 978-3-31-955780-9
Authors

Grant A. Mitchell, Hao Yang

Abstract

This chapter provides a clinical perspective on the challenges that stand between current clinical practice and a cure for hepatorenal tyrosinemia (HT1). HT1 has been transformed in the last 50 years from an aggressive often undiagnosed childhood disease causing liver failure or liver cancer, with infant death in most patients, to a condition that is detectable at birth, and for which treatment with nitisinone (NTBC) and diet can prevent detectable liver or kidney abnormalities. What challenges remain? The properties of the affected metabolic pathway and the broad spectrum of severity seen in untreated patients are incompletely understood but potentially important for patients. Available treatments have potential complications, including liver transplantation (risks of surgery and of immunosuppression to prevent rejection), nitisinone and diet therapy (hypertyrosinemia, corneal opacities, nutritional imbalances and possibly developmental delay). The detection of liver cancer is imperfect and laborious. The effects of tyrosinemia during pregnancy are little-known. Although animal models of HT1 are becoming standard research tools in cell replacement and gene modification therapy, these techniques are not currently applicable to HT1 itself. Treatment adherence is variable, causing concern about long term outcome for some patients. Around the world, there are great disparities in the diagnosis and treatment of HT1. Most affected individuals are born in places where newborn screening for HT1 is not performed and where appropriate treatment is not available. We hope that this list will help to focus on some of these remaining obstacles to a cure for HT1.

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 13 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 46%
Student > Master 2 15%
Student > Bachelor 1 8%
Student > Doctoral Student 1 8%
Other 1 8%
Other 0 0%
Unknown 2 15%
Readers by discipline Count As %
Nursing and Health Professions 2 15%
Medicine and Dentistry 2 15%
Psychology 2 15%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Business, Management and Accounting 1 8%
Other 2 15%
Unknown 3 23%